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Insulin receptorInsulin-induced insulin receptor (IR) tyrosine kinase activation and insulin cell survival responses have been
reported to be under the regulation of a membrane associatedmammalian neuraminidase-1 (Neu1). Themolec-
ular mechanism(s) behind this process is unknown. Here, we uncover a novel Neu1 and matrix
metalloproteinase-9 (MMP-9) cross-talk in alliance with neuromedin B G-protein coupled receptor (GPCR),
which is essential for insulin-induced IR activation and cellular signaling. Neu1, MMP-9 and neuromedin B
GPCR forma complexwith IRβ subunit on the cell surface. Oseltamivir phosphate (Tamiﬂu®), anti-Neu1 antibod-
ies, broad range MMP inhibitors piperazine and galardin (GM6001), MMP-9 speciﬁc inhibitor (MMP-9i), and
GPCR neuromedin B speciﬁc antagonist BIM-23127 dose-dependently inhibited Neu1 activity associated with
insulin stimulated rat hepatoma cells (HTCs) that overly express human IRs (HTC-IR). Tamiﬂu, anti-Neu1 anti-
bodies and MMP-9i attenuated phosphorylation of IRβ and insulin receptor substrate-1 (IRS1) associated with
insulin-stimulated cells. Olanzapine, an antipsychotic agent associated with insulin resistance, induced Neu3
sialidase activity in WG544 or 1140F01 human sialidosis ﬁbroblast cells genetically defective in Neu1. Neu3 an-
tagonist 2-deoxy-2,3-didehydro-N-acetylneuraminic acid (DANA) and anti-Neu3 antibodies inhibited sialidase
activity associated with olanzapine treated murine Neu4 knockout macrophage cells. Olanzapine attenuated
phosphorylation of IGF-R and IRS1 associatedwith insulin-stimulated humanwild-type ﬁbroblast cells. Our ﬁnd-
ings identify a novel insulin receptor-signaling platform that is critically essential for insulin-induced IRβ tyrosine
kinase activation and cellular signaling. Olanzapine-induced Neu3 sialidase activity attenuated insulin-induced
IGF-R and IRS1 phosphorylation contributing to insulin resistance.




acid; IC50, the concentration of
oll-like receptor; GPCR, G-pro-
inase; IGF-1, insulin like growth
platelet-derived growth factor;
; EGF, epidermal growth factor;
αi,α subunit of Gi; Grb, growth




, Serology, Jeddah, Saudi Arabia.
Ottawa, Ottawa, ON K1N 6N5,
s, Cleveland Clinic Foundation
Ohio, U.S.A.
cMaster University, Hamilton,
versity of Alberta, Edmonton,
.Open access under CC BY-NC-ND lice1. Introduction
The insulin receptor (IR) is a transmembrane tyrosine kinase re-
ceptor that is activated by insulin and insulin growth factors-I and
II. Metabolically, insulin-induced IR tyrosine kinase activation
plays a key role in the regulation of glucose homeostasis. A dys-
functional process of insulin induced IR activation may result in a
range of clinical manifestations including insulin resistance [1],
type 2 diabetes (T2DM), obesity, cancer, hypertension, and cardio-
vascular disorders [2–5]. In particular, insulin resistance occurs
when the insulin-sensitive tissues, such as skeletal muscle, adipose
tissue and liver, do not have the ability to respond to insulin [6,7],
and consequently develop several of these chronic diseases
[8–10]. The precise mechanism(s) involved in insulin resistance is
not well understood [1]. However, several contributing factors
have been proposed to contribute to insulin resistance, and they in-
clude increased plasma-free fatty acid levels [11], elastin-derived
peptides [12], subclinical chronic inﬂammation [1], oxidative and
nitrative stress, altered gene expression, and mitochondrial dys-
function [1,11].nse.
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insulin resistance and cell membrane sialic acid content. Cytidine 5′-
monophospho-N-acetylneuraminic acid (CMP-NANA; substrate used
for the sialyltransferase sialylation of glycans) was reported to enhance
insulin responsiveness by 39% providing support for a role for cell sur-
face sialic acid residues in hepatic insulin action with a concomitant
contribution to insulin resistance of diabetes mellitus [13]. Structurally,
IR is a heavily glycosylated receptor with 18 glycosylation sites [14,15].
Fourteen of the glycosylation sites are localized on the IRα subunits,
while the other sites are on the IRβ subunits [16]. Speciﬁcally, the IRα
subunits contain only the N-linked carbohydrate, while IRβ subunits
contain both O- and N-linked carbohydrates [17].
The importance of glycosylation in IR biosynthesis, insulin binding
and activation has been studied in detail using site-directed mutagene-
sis analyses [16,18]. Leconte et al. reported on the potential contribution
of N-linked oligosaccharides of the IRβ subunit in the processing, struc-
ture and function of the IR [18]. They speciﬁcally targeted and mutated
IRβ subunits (IRβ-N1234) which were mutagenized on four potential
N-glycosylation sites (ASn-X-Ser/Thr). They compared the mutated IR-
N1234 with the wild type receptor. There were no differences on the
molecular weight of IRα subunits between both receptors. However, a
reduction in themolecularweight from95 kDa to 80 kDa of the IRβ sub-
unit was depicted in the mutated IR form. The data indicated that the
mutation of the four glycosylation sites in IRβ subunit had no effect on
the α-subunit, but caused a reduction in the β-subunit molecular
weight. This IRβ-N1234mutation hadno effect on IR cell surface expres-
sion and on insulin binding, but attenuated IRβ tyrosine kinase activa-
tion by insulin [18]. These early ﬁndings provided supporting evidence
for a critical role of oligosaccharide side chains of the IRβ subunit in
the molecular events responsible for the IR enzymatic activation and
signal transduction. Indeed, the role of membrane glycosylation in the
function of insulin receptors and glucose transporters is well known
for two decades. A neuraminidase was found to release sialic acid
from isolated rat adipocytes [19]. The report disclosed that
pretreatment of adipocytes with a neuraminidase resulted in an
increase in basal glucose transport, the process of which suggested
sialic acids playing multiple roles in the control of glucose-transport
activity.
Recently, the treatment of rat skeletal L6 myoblast cells with either
mouse-derived mammalian Neu1 sialidase or Clostridium perfringens
neuraminidase resulted in a desialylation of IR, which coincided with a
signiﬁcant increase of L6 myoblast cell proliferative responses to low
concentrations of insulin [20]. In addition, the inhibition of endogenous
Neu1 abolished this increase in proliferation of L6 cells induced by 1 and
10 nMof insulin, but ampliﬁed the proliferative effect of 100 nM insulin.
For IGF receptors, the opposite results were observed where the
desialylation process of this receptor coincided with an elimination of
the heightened proliferative response of L6 myoblasts to 100 nM insu-
lin. To explain this dichotomy, it was proposed that Neu1 enhanced
the mitogenic response of L6 myoblasts to low dose of insulin, but the
cytosolic Neu2 sialidase [21] and the cell membrane-bound Neu3
sialidase induced myoblast differentiation, but not proliferation,
through the direct modulation of the GM3 ganglioside content in myo-
blasts [22,23]. In support of this hypothesis, it has been reported that a
transient upregulation of Neu3 expression in L6 myocytes caused a
signiﬁcant decrease in IR signaling, the mechanism of which was pro-
posed to be in direct modulation of plasma membrane gangliosides by
Neu3 activity and the interaction with the growth factor receptor-
bound protein 2 (Grb2) [24].
Another possibility to explain this dichotomy of insulin-inducedmi-
togenic responses may involve GPCR-receptor tyrosine kinase (RTK)
partners forming novel signaling platforms. Using human embryonic
kidney 293 cells, Alderton et al. have clearly demonstrated that the
platelet-derived growth factor β receptor (PDGFβR) forms a complex
withMyc-tagged endothelial differentiation gene-1, a GPCRwhose ago-
nist is sphingosine 1-phosphate, in cells co-transfected with thesereceptors [25]. PDGF was shown to stimulate tyrosine phosphorylation
of the inhibitory Giα subunit to increase p42/p44 mitogen activated
protein kinase (MAPK) activation in the regulation of cell proliferation.
Furthermore, both GPCR kinase 2 and β-arrestin-1 were found to asso-
ciate with the PDGFβR, which play critical roles in the regulation of
GPCR signal complexes endocytosis, a requirement for the activation
of p42/p44 MAPK. The premise is that PDGFβR signaling is initiated by
GPCR kinase 2/β-arrestin-1 complexes that have been recruited to the
PDGFβR via tethering to a GPCR(s). These results provide a novel
platform for the integrative signaling by these receptors that may
account for the co-mitogenic effect of certain GPCR agonists with
PDGF on cell proliferation. It is noteworthy that the basally tyrosine-
phosphorylated Giα subunits do not induce activation of p42/p44
MAPK on their own [25]. The potentiating effects of Giα signaling on
the PDGF-stimulated p42/p44 MAPK activation may require the PDGF-
induced recruitment to tyrosine-phosphorylated Giα subunits of other
intermediates. Indeed, several reports have shown that insulin
receptors can interact with Giα subunit [26–28]. The integration of
GPCR-RTK partners forming unique signaling platforms in which pro-
tein components speciﬁc for each receptor are shared to produce a
response upon engagement of ligands is eloquently reviewed by Pyne
and colleagues [29–32] and Abdulkhalek et al. [33].
Recently, insulin binding to its receptor was reported to rapidly in-
duce the interaction of the insulin receptor with Neu1 sialidase, the ac-
tivity of which hydrolyzes sialic acid residues of IR and, consequently,
induces receptor activation [34]. The report also disclosed that Neu1
deﬁcient mice with ∼10% of the normal Neu1 activity exposed to a
high-fat diet developed hyperglycemia and insulin resistance twice as
fast as the wild-type cohort. They also proposed that endogenous
Neu1 sialidase activity is involved in the insulin receptor glycosylation
modiﬁcation. Indeed, Blaise et al. provided additional conﬁrmation to
support that Neu1 interacts with IRβ and desialylates the receptor
[12]. Other reports have suggested that receptor glycosylation
modiﬁcation may in fact be the connecting link between ligand-
binding, receptor dimerization and activation for several other recep-
tors [35–39].
This present report describes a novel organizational IR signaling
platform describing the intermediates linked to the insulin-induced re-
ceptor activation process in live IR-expressing cells. Here, insulin bind-
ing to its receptor induces a Neu1 and matrix metalloproteinase-9
(MMP-9) cross-talk in activating IRs. Central to this process is that
Neu1 and MMP-9 cross-talk in alliance with neuromedin B GPCR
forms a complex tethered at the ectodomain of IRβ subunits on the
cell surface. This signaling paradigm proposes that insulin binding to
its receptor on the cell surface induces a conformational change of
the receptor to initiate GPCR Giα-signaling and MMP-9 activation to
induce Neu1. Activated Neu1 hydrolyzes α-2,3-sialyl residues linked
to β-galactosides, which are distant from the insulin binding sites.
These ﬁndings are consistent with another report [34] that predicts a
prerequisite desialylation process by activated Neu1 enabling the
removal of steric hindrance to IRβ subunit association and the activation
of tyrosine kinases. This Neu1-MMP-9 crosstalk in alliance with
neuromedin B GPCR at the ectodomain of IRβ subunits forms the essen-
tial signaling platform on the cell surface that is critical for insulin-
induced receptor activation.
Olanzapine, an antipsychotic agent associated with insulin resis-
tance [40–42], induced Neu3 sialidase activity in Neu1-deﬁcient
human WG544 or 1140F01 sialidosis ﬁbroblast cells and Neu4
knockout primary murine macrophage cells. Olanzapine-induced
Neu3 activity attenuated IRβ and IRS1 phosphorylation associated
with insulin-stimulated human ﬁbroblast cells. This study provides
conﬁrmation additional evidence that Neu1 sialidase is involved in
the regulation of insulin signaling and that a down-regulation
Neu1 by Neu3 activity may lead to an impaired insulin receptor
signaling and subsequently contributing to insulin-resistant
diabetes.
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2.1. Cell lines
HTC-WT cell line is the wild-type rat hepatoma cell line and HTC-IR
cells, a rat hepatoma cell line that overly expresses the human insulin
receptors [43] (kindly provided by Dr. Leda Raptis, of this department).
The cell lines were grown in 1× Dulbecco's Modiﬁed Eagle Medium
(DMEM, Gibco, Rockville, MD) containing 10% fetal calf serum (FCS)
(HyClone, Logan, Utah, USA) and 5 μg/mL plasmocin, and were main-
tained at 5% CO2 and 37 °C. For HTC-IR cell line, the medium was sup-
plemented with 400 μg/mL of G418 as selection marker for IR
expression.
WG544 or 1140F01 sialidosis ﬁbroblast cell line is a Neu1 deﬁcient
skin ﬁbroblast cells that were isolated from patients with lysosomal
storage disorder type 1 sialidosis and immortalized [44]. Wild-type
human ﬁbroblast cell line is a normal skin ﬁbroblast cells. Primary
bone marrow (BM) macrophage cells were obtained Neu4 knockout
mice [45]. These cells were kindly provided by Dr. Alexey Pshezhetsky,
Department of Pediatrics and Biochemistry, Montreal University, Ser-
vice de Genetique, Ste-Justine Hospital, 3175 Cote-Ste-Catherine,
H3T1C5, Montreal, QC, Canada. Cells were grown in 1× DMEMmedium
containing 10% FCS and 5 μg/mL plasmocin. The primary BM
macrophage cells were further supplemented with 20% (v/v) of L929
cell supernatant as a source of monocyte colony-stimulating factor
(M-CSF).
2.2. Primary mouse bone marrow macrophage cells
Bone marrow (BM) cells were ﬂushed from femurs and tibias of
micewith sterile Tris-buffered saline (TBS) solution. The cell suspension
was centrifuged for 3min at 900 rpm, and the cell pellet resuspended in
red cell lysis buffer for 5 min. The remaining cells were washed once
with sterile TBS, and then resuspended in RPMI conditioned medium
supplemented with 10% FBS and 20% (v/v) of L929 cell supernatant as
a source of monocyte colony-stimulating factor (M-CSF) according to
Alatery and Basta [46] and 1× L-glutamine-penicillin–streptomycin
(Sigma-Aldrich Canada Ltd., Oakville, Ontario) sterile solution. The pri-
mary BM macrophages were grown on 12 mm circular glass slides in
RPMI conditioned medium for 7–8 days in a humiﬁed incubator at
37 °C and 5% CO2. Primary BM macrophage cells by day 7 are more
than 95% positive for macrophage marker F4/80 molecule as detected
by ﬂow cytometry.
2.3. Reagents
The active substance in Novolin®ge (Insulin, Human Biosynthetic) is
a polypeptide that is structurally identical to natural human insulin. The
insulin is produced by recombinant DNA technology in Saccharomyces
cerevisiae. Human insulin (Novolin®ge Toronto) is an injectable solu-
tion, 3.5 mg (100 IU) of the natural ligand of the insulin receptors, and
stored at 4 °C. The injectable insulin solution was used in our experi-
ments at a concentration range of 10–100 nM. This concentration was
determined to produce optimal insulin-induced sialidase activity
based on the results of our live cell sialidase assay. Incubation times
vary between experiments and are indicated.
2-(4-Methylumbelliferyl)-α-D-N-acetylneuraminic acid (4-MUN-
ANA; Biosynth Intl.) is a sialidase substrate thatwas used at a concentra-
tion of 0.318 mM in the sialidase experiments.
Olanzapine (OLZ) is an antipsychotic drug sold under the brand
name, Zyprexa (Eli Lilly Canada Inc., Toronto, ON, M1N 2E8).
2.4. Inhibitors
Oseltamivir phosphate, Tamiﬂu (99% pure oseltamivir phosphate,
Hoffmann-La Roche Ltd.), a broad-range sialidase inhibitor was used at200–300 μg/mL unless otherwise indicated. DANA (2-deoxy-2,3-
dehydro-D-N-acetylneuraminic acid) (Sigma-Aldrich) were used at indi-
cated concentrations. Pertussis toxin (PTX, from Bordetella pertussis, in
buffered aqueous glycerol solution, Sigma-Aldrich) catalyzes the ADP-
ribosylation of the α subunits of the heterotrimeric G proteins Gi, Go,
and Gt. This prevents the G protein heterotrimers from interacting with
receptors, thus blocking their coupling and activation. Galardin
(GM6001; Calbiochem-EMD Chemicals Inc., Darmstadt, Germany) is a
potent, cell-permeable, broad-spectrum hydroxamic acid inhibitor
of matrix metalloproteinases (MMPs) (IC50 = 400 pM for MMP1;
IC50 = 500 pM for MMP2; IC50 = 27 nM for MMP3; IC50 = 100 pM
for MMP8; and IC50 = 200 pM for MMP9). Galardin was used at a con-
centration of 12.5 ng/mL to 125 μg/mL for the indicated incubations
times. Piperazine (PIPZ; MMPII inhibitor; Calbiochem-EMD Chemicals
Inc.) is a potent, reversible, broad range inhibitor of matrix metallopro-
teinases. PIPZ inhibits MMP1 (IC50 = 24 nM), MMP3 (IC50 = 18.4 nM),
MMP7 (IC50 = 30 nM), and MMP9 (IC50 = 2.7 nM). PIPZ was used at a
concentration of 12.5 ng/mL to 125 μg/mL for the indicated incuba-
tions times. MMP-9-inhibitor (MMP-9i; Calbiochem) is a speciﬁc and
reversible inhibitor of MMP-9. MMP-9i was used at concentrations of
50 μg/mL or 100 μg/mL. MMP-3-inhibitor (MMP-3i; Calbiochem) is a
speciﬁc and reversible inhibitor ofMMP-3.MMP-3iwas used at concen-
trations of 125 ng/mL to 125 μg/mL.
Cyclolignan picropodophyllin (PPP; Calbiochem) was used to dis-
criminate between insulin receptor phosphorylation and insulin-like
growth factor-1 receptor phosphorylation by inhibiting IGF-1. PPP is a
non-competitive inhibitor that was used at a concentration of 20 nM.
BIM-23127 is a speciﬁc neuromedin B receptor inhibitor from Tocris
Bioscience (Tocris House, IO Centre Moorend Farm Avenue, Bristol,
BS11 0QL, United Kingdom).2.5. Primary antibodies
The expression of insulin receptors was determined by using anti-
body speciﬁc for IRβ (C-19; Santa Cruz Biotechnology). IRβ antibody is
a rabbit anti-human antibody that is raised against a peptide mapping
at the C-terminus of IRβ of human origin. Insulin receptor activation
and tyrosine kinase phosphorylationwas determined by using two spe-
ciﬁc antibodies. The anti-phosphorylated insulin receptorβ (p-IRβ;MBL
International, Woburn, MA 01801) antibody is a rabbit anti-human an-
tibody that is raised against a chemically synthesized phospho-peptide
derived from the region of the human insulin receptor that contains
tyrosine 972. The anti-phosphorylated insulin receptor substrate-1
(p-IRS-1; Cell Signaling Technology, Inc.) is a rabbit anti-human anti-
body speciﬁc for phosphorylated insulin receptor substrate-1 (p-IRS).
Inwestern blot experiments, horse radish peroxidase (HRP) conjugated
goat anti-rabbit IgG antibody (Sigma Aldrich) was used as a secondary
antibody. In the co-immunoprecipitation experiments, CleanBlot IP
Detection Reagent (Pierce, Cell Signaling Technology, Inc.) was used
as a secondary antibody. CleanBlot reagent is a conjugated HRP anti-
body that has the ability to bind to the native antibody and not the de-
natured antibody fragments from the immunoprecipitation processing
step. In the immunocytochemistry and the co-localization experiments,
donkey anti-rabbit AlexaFluor 488 or donkey anti-rabbit AlexaFluor 594
antibodies (Molecular Probes, Life Technologies, Carlsbad, CA, 92008.
United States) were used as secondary antibodies.
Four neutralizing antibodies were used to inhibit sialidase activity in
live HTC-IR and primarymurinemacrophage cell lines. The neutralizing
antibodies are rabbit-anti-human Neu1 IgG antibody (Santa Cruz Bio-
technology, Inc.), mouse anti-human Neu2 IgG antibody (Santa Cruz),
mouse anti-human Neu3 IgG antibody (MBL) and rabbit anti-human
Neu4 IgG antibody (Proteintech Group, Inc., Chicago, IL 60612, USA).
Goat anti-human MMP9 IgG antibody (Santa Cruz) was used in order
to identify the role of MMP9 in insulin receptor activation and its effect
on the phosphorylation of the receptor.
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Cells were grown overnight on 12 mm circular glass slides in condi-
tioned medium in a sterile 24-well tissue plate until they reached ~70%
conﬂuence as previously optimized in the live cell sialidase assay
[47,48]. After removingmedium, 0.318mM4-MUNANA (2′-(4-methyl-
umbelliferyl)-α-D-N-acetylneuraminic acid; Biosynth Intl.) substrate in
Tris-buffered saline (TBS) pH 7.4 was added to each well alone (con-
trol), with predetermined dose of insulin, or in combination of insulin
and inhibitor or neutralizing antibodies at the indicated concentrations.
The stimulated group was treated with insulin at indicated concentra-
tions (10–100 nM) in the presence or absence of PPP (IGF-1R inhibitor).
The inhibited group was pretreated with different inhibitors
(oseltamivir phosphate, anti-Neu-1, -2, -3, and -4 neutralizing
antibodies, piperazine, galardin, MMP9 inhibitor and MMP3 inhibitor)
at indicated concentrations followed with insulin stimulation. The
sialidase substrate 4-MUNANA at 0.318 mM was added to the cells in
order to detect sialidase activity. The substrate is hydrolyzed by sialidase
to give free 4-methylumbelliferone, which has a ﬂuorescence emission
at 450 nm (blue color) following an excitation at 365 nm. Fluorescent
images were taken after 2–3 min using epi-ﬂuorescent microscopy
(Zeiss Imager M2, ×40 objective). Sialidase activity of live HTC-IR cells
was indicated by the blue ﬂuorescence surrounding the periphery of
the cells. The mean ﬂuorescence was calculated using Image J software.
2.7. Immunocytochemistry for phosphorylation of IRβ in insulin-treated
HTC-IR cells
HTC-IR cells were cultured on 12 mm glass coverslips in a sterile
24 well plate in conditional medium as previously described. After
cells reached about 70% conﬂuence, cells were serum starved for 4 h.
Cells were either control non-treated cells or secondary antibody only
control, or pretreated cells. Pretreated cells were either stimulated by
(100 nM) insulin accompanied with PPP for 5 min, or treated with
oseltamivir phosphate (350 μg/mL) for 30 min followed by insulin
(10-100 nM). Control cells were neither inhibited nor stimulated. Cells
were ﬁxed with 4 μg/mL paraformaldehyde for 30 min and perme-
abilizedwith 0.2% Triton-X for 5min. Cells were blockedwith 4% bovine
serum albumin (BSA) in 0.1% tween-TBS for 40 min on ice. The ﬁxed
cells were immunostained with 4 μg/mL rabbit anti-human pIRβ anti-
body for 1 h at 37 °C, followed with AlexaFluor 488 conjugated donkey
anti-rabbit IgG antibody for 1 h at 37 °C. In order to detect the non-spe-
ciﬁc ﬂuorescence background, control cells were incubated with
secondary antibody only. Stained cells were viewed by ﬂuorescence
microscopy (40× magniﬁcation). The density of the cell staining
(green ﬂuorescence) was measured by Corel Photo Paint 8.0 software.
2.8. Preparation of cell lysates
HTC-IR cells were cultured in 75 cm2 ﬂasks at 37 °C until conﬂuent.
Cells were treated with insulin, pretreated with different inhibitors
followed with insulin, or left untreated as control cells. Cells were re-
moved and re-suspend in 100 μL of RIPA lysis buffer cocktail which
contains 1× RIPA buffer, 1 mM PMSF, 0.2 mg/mL leuptin, 1% β
mercaptoethanol and 1 μL protease inhibitor cocktail on ice for
30 min. Cell suspension was then transferred into other Eppendorf
tubes and stored at−80 °C.
2.9. Western blot to detect insulin receptor β (IRβ) and human phosphory-
lated insulin receptor substrate-1 (pIRS-1)
Cell lysates were prepared from the following cell lines: HTC-IR,
HTC-WT and MiaPaCa-2. Cells (1 × 107 cells) were pelleted and lysed
in lysis buffer (50 mM Tris, pH 8, 150 mM NaCl, 1% Nonidet P-40,
0.2 mg/mL leupeptin, 1% β-mercaptoethanol, and 1 mM PMSF). The
protein samples were denatured in the lysis buffer at 95–100 °C for8 min. To ensure the best resolution, samples were mixed before and
after heating. Proteins in the cell lysates were resolved by 8% Bis–Tris
SDS-PAGE gel. The gel running time was 90 min at 150 V. Semi dry
transfer technique was performed to transfer the resolved proteins on
PVDF transfer membrane blot. Transfer time was 75 min at 100 mA.
The membrane blot was blocked for 2 h at room temperature or over-
night at 4 °C using 5% BSA or fat-free skimmilk in 0.1% Tween-Tris buff-
ered saline (TBS) to block non-speciﬁc background binding. The blot
was probed with rabbit anti-insulin receptor β (IRβ) antibody or rabbit
anti-human phosphorylated insulin receptor substrate-1 (pIRS-1) anti-
body (Cell Signaling) as primary antibodies overnight at 4 °C. After in-
cubating, the blot was washed three times followed with horse radish
peroxidase (HRP) conjugated secondary goat anti-rabbit IgG antibody
for 60min at room temperature andWestern Lightning Chemilumines-
cence Reagent Plus for 5 min. The chemiluminescence reaction was an-
alyzed with X-ray ﬁlm. The blot was washed, stripped and re-probed
with anti-β-actin antibody (Cell Signaling) as an internal control protein
for loading of the cell lysate. Quantitative analysiswas done by assessing
the density of a band corrected for background in each lane using Corel
Photo Paint 8.0 software. Each bar in the graphs represents the mean
ratio of IRβ to β-actin of band density ± S.E. (error bars) for 5–10 repli-
cate measurements.
2.10. Co-immunoprecipitation
HTC-IR cells were left cultured in medium or in medium containing
100 nM insulin for the indicated time intervals. Cells (1 × 107 cells)
were pelleted and lysed in lysis buffer (50 mM Tris, pH 8, 150 mM
NaCl, 1% Nonidet P-40, 0.2 mg/mL leupeptin, 1% β-mercaptoethanol,
and 1 mM PMSF). For immunoprecipitation, Neu-1, -2 and -4, MMP9
and insulin receptor in cell lysates from HTC-IR cells using 100 μg of
cell lysates were immunoprecipitated with either 1 μg of rabbit-anti-
human Neu1 antibody, mouse anti-human Neu2 antibody, rabbit anti-
human Neu4 antibody or goat anti-human MMP9 antibody overnight
at 4 °C. Following immunoprecipitation, complexes were isolated
using protein A or G magnetic beads for 90 min, washed three times
in buffer (10 mM Tris, pH 8, 1 mM EDTA, 1 mM EGTA, 150 mM NaCl,
1% Triton X-100, and 0.2 mM sodium orthovanadate) and resolved by
8% Bis–Tris gel electrophoresis (SDS-PAGE). The gel's running time
was 90 min at 150 V. The proteins were transferred onto PVDF transfer
membrane blot via semi-dry blotting technique for 75 min at 100 mA.
The blot was blocked with 5% BSA in 0.1% Tween-TBS as blocking buffer
for 2 h at room temperature. The blot was incubated with rabbit anti-
human IRβ antibody overnight at 4 °C followed with Clean-Blot IP De-
tection Reagent for immunoprecipitation/western blots (Pierce, Thermo
Fisher Scientiﬁc) for 60 min at room temperature and Western Light-
ning Chemiluminescence Reagent Plus. The chemiluminescence
reaction was analyzed with X-ray ﬁlm. HTC-IR cell lysates that were
not incubated with the IRβ antibody prior to the immunoprecipitation
step were used as a negative control in the co-IP experiments. Blot
was washed, stripped and re-probed with anti-insulin receptor
antibody in order to determine equal loading.
2.11. Neu1 and MMP9 co-localization with insulin receptor β (IRβ)
HTC-IR cells were cultured on 12 mm circular glass coverslips in a
sterile 24 well plate in conditional medium as described. After cells
reached about 70% conﬂuence, cells were serum starved for 4 h. Cells
were ﬁxed with 4 μg/mL paraformaldehyde, permeabilized with
Triton-X, and blocked with 4% BSA in 0.1% Tween-TBS for 40 min on
ice. Cells were incubated with 4 μg/mL of one of the following combina-
tions of antibodies (IRβ antibody and Neu1 antibody; IRβ antibody and
Neu2 antibody; IRβ antibody and Neu3 antibody; IRβ antibody and
Neu4 antibody; or IRβ antibody and MMP9 antibody) for 60 min at
37 °C. Co-localization procedure is dependent on the primary antibody
combination with respect to animal species. Cells were washed and
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ed secondary antibodies for 60min at 37 °C. To account for background
non-speciﬁc ﬂuorescence, control cells with only AlexaFluor 488 or
AlexaFluor 594 conjugated secondary antibody were used. Stained
cells were mounted on microscope slide using 3 μL of mounting medi-
um (DAKO). Stained cells were viewed using Zeiss M2 epi-ﬂuorescent
microscopy (40× objective). Images were taken under two different
channels; red channel and green channel. Overlay and co-localization
visualization was done by using Adobe Photoshop software and Image
J software. To calculate the amount of colocalization in the selected im-
ages, the Pearson correlation coefﬁcientwasmeasured and expressed as
a percentage using Image J version 1.38x software.
2.12. Statistical analysis
Statistical analysis was performed by using GraphPad Prism 5.0.
Comparisons between two groups were made by one-way analysis of
variance at 95% conﬁdence using Student's unpaired t test and
Bonferroni's multiple comparison test or Dunnett's multiple compari-
son test for comparisons among more than two groups.
3. Results
3.1. Neu1 sialidase activity is associated with insulin stimulation of insulin
receptor (IR)-expressing cells
Insulin binding to its receptor has been reported to rapidly induce
the interaction of the IRwithNeu1 [34]. Activated Neu1 hydrolyzes sial-
ic acid residues of the receptor and, consequently, induces IR activation.
The report also disclosed that Neu1 deﬁcientmicewith∼10% of the nor-
mal Neu1 activity fed a high-fat diet rapidly developed hyperglycemia
and insulin resistance. Collectively, this report and other reports
[19,20] suggest that insulin receptor glycosylation modiﬁcation may
be the link connecting insulin-binding and receptor activation, but the
mechanism(s) behind this linkage is unknown. Recently, we reported
that epidermal growth factor (EGF) binding to EGF receptors potenti-
ates neuromedin B GPCR-signaling and MMP-9 activation to induce
Neu1 activity in live EGFR-expressing cell lines [39]. A striking similarity
was identiﬁed between this novel receptor signaling platform for nerve
growth factor (NGF) TrkA receptors [49], cell surface Toll-like receptor
(TLR)-4 [48,50,51], and intracellular TLR-7 and TLR-9 receptors [52].
Since IRs belong to the same family of receptor tyrosine kinases like
EGFR and TrkA, we initially askedwhether insulin-induced IR activation
follows this similar receptor signaling paradigm.
Using a rat hepatoma cell line overly expressing human IR (HTC-IR),
we performed a sialidase assay on the live cells as previously described
[48,53,54]. As shown in Fig. 1A, insulin stimulation of live HTC-IR
cells dose-dependently induced sialidase activity. This sialidase activity
is revealed in the periphery surrounding the cells using a ﬂuorogenic
sialidase speciﬁc substrate, 4-MUNANA [2′-(4-methylumbelliferyl)-α-
D-N-acetylneuraminic acid], which ﬂuoresces at 450 nm and caused
by the emission of 4-methylumbelliferone. The mean ﬂuorescence of
50 multi-point replicates was quantiﬁed using the Image J software
and is depicted in the bar graph. We also used speciﬁc neutralizing an-
tibodies against the fourmammalian sialidases [55], known as lysosom-
al Neu1 [56–62], cytosolic Neu2, the plasma membrane bound Neu3
[24,63,64] and the fourth sialidase, Neu4, localized to either the mito-
chondrial [65] compartment or the lysosomal lumen [66]. As shown in
Fig. 1B, anti-human Neu1 antibody blocked the sialidase activity associ-
atedwith insulin-treated live HTC-IR cells comparable to the levels of no
insulin treated controls. The anti-Neu1 antibody used here is speciﬁc for
the epitope corresponding to amino acids 116–415 mapping at the C-
terminus of Neu1 of human origin. It also detects Neu1 of mouse, rat
and human origin. In contrast, antibodies against the other three
human sialidases, Neu-2, -3 and -4 had no blocking effect on sialidase
activity associated with insulin stimulated live HTC-IR cells similar tothe mean ﬂuorescence levels of insulin positive control (Fig. 1B).
These latter results using neutralizing antibodies are consistent with
our previous report with Toll-like receptors [54]. It was not surprising
that this insulin-induced sialidase activity was completely blocked by
the neuraminidase inhibitor Tamiﬂu (pure oseltamivir phosphate) at
200 μM as shown in Fig. 1C but also in a dose dependent range of
0.25–250 μg/mL (Fig. 1C). To further elucidate the inhibitory capacity
of Tamiﬂu, the 50% inhibitory concentration (IC50) of the compound
was determined by plotting the decrease in sialidase activity against
the log of the agent concentration. As shown in Fig. 1C, Tamiﬂu had an
IC50 of 60 μM which is slightly higher than the reported IC50 of
3.876 μM for NGF-TrkA [49] and 1.175 μM for LPS-TLR-4 [54] ligand-
induced sialidase activity in TrkA-PC12 and BMC-2 macrophage cells,
respectively. For NGF-induced sialidase activity in TrkA-expressing
cells, we also reported that other puriﬁed neuraminidase inhibitors
such as zanamivir (4-guanidino-Neu5Ac2en) and oseltamivir carboxyl-
ate had a limited inhibition of NGF-induced sialidase activity in live
TrkA-PC12 cells at 1–2 mM compared to the NGF positive control [49].
Other studies using recombinant soluble human sialidases have
shown that oseltamivir carboxylate, the active metabolite of Tamiﬂu,
scarcely inhibited the activities of the four human sialidases even at
1 mM [67], while zanamivir signiﬁcantly inhibited the human Neu2
and Neu3 sialidases in the micromolar range. Zanamivir and DANA (2-
deoxy-2,3-didehydro-N-acetylneuraminic acid) were found to inhibit
endogenous sialidase activity of activated lymphocytes grown in
culture, as evidenced by an altered sialylation pattern of cell surface pro-
teins, and that this inhibition of sialidase activity resulted in a reduced
production of IFN-γmRNA and protein in the 1–2 mM range [58].
To conﬁrmNeu1 sialidase activity associatedwith insulin stimulated
live cells at the genetic level, we used humanWG544 or 1140F01 type 1
sialidosis ﬁbroblast cell lines with the live cell sialidase assay. Patients
with type 1 sialidosis or mucolipidosis-1 have a Neu1 genetic deﬁciency
which is a human autosomal recessive inborn error of metabolic
disease. Patients with sialidosis have a build-up of sialylated
glycoconjugates in tissues and urine causing neuropathic or non-
neuropathic symptoms depending on the onset of the disease. The
data in Fig. 1D clearly indicate a lack of sialidase activity associated
with insulin stimulation of these live Neu1-deﬁcient cells compared to
thewild-type human ﬁbroblast cells. These latter data provide addition-
al supporting evidence for Neu1 involvement with insulin activation of
live IR expressing cells. It is noteworthy that the ﬂuorescence associated
with ligand treated cells as seen in Fig. 1 is not due to a form of secreted
or shed sialidase from the cells as previously described [53,54]. The live
cells treated with the substrate alone do not show ﬂuorescence sur-
rounding the cells, consistent with our other reports [49,54]. Taken to-
gether, these results suggest that the diffuse ﬂuorescence associated
with insulin treated live cells is due to an activation of Neu1 on the
cell surface.
3.2. Insulin-induced phosphorylation of insulin growth factor-1 receptor
(IGF-1R), insulin receptor substrate-1 (IRS-1) and insulin receptor β
(IRβ) is dependent on Neu1 sialidase activity
If insulin-induced receptor phosphorylation is dependent on Neu1
activity, then neuraminidase inhibitor like Tamiﬂu or anti-Neu1 neu-
tralizing antibody should have an inhibitory effect on insulin-induced
phosphorylation of IGF-1R, IRS-1 and IRβ in IR-expressing cells. Immu-
nocytochemistry analyses shown in Fig. 2A demonstrate that Tamiﬂu,
anti-Neu1 antibody and Gαi protein inhibitor pertussis toxin (PTX)
signiﬁcantly inhibited insulin-induced pIGF-1R and pIRS-1 in wild-
type human ﬁbroblast cells compared to the insulin treated controls.
Western blot analyses conﬁrmed that Tamiﬂu and anti-Neu1 antibodies
markedly inhibited insulin-induced pIRS-1 in HTC-IR cells compared to
the insulin treated controls (Fig. 2B). To test the inhibitory effect of
Tamiﬂu on insulin-induced phosphorylation of IRβ, HTC-IR cells were
left untreated as controls, and either stimulated with 100 nM insulin
Fig. 1. (A) Insulin induces sialidase activity in live HTC-IR cells in a dose-dependent manner. HTC-IR cells were allowed to adhere on 12 mm circular glass slides in media containing 10%
fetal calf sera for 24 h. After reaching ~75% conﬂuence, cells were serum starved for 6 h. After removingmedia, 0.318mM 4-MUNANA (4-MU) substrate (2′-(4-methlyumbelliferyl)-α-N-
acetylneuraminic acid) in Tris buffered saline pH7.4 was added to live cells alone (control) or with insulin at the indicated doses together with 50 nM PPP. The substrate is hydrolyzed by
sialidase enzymes to give free 4-methylumbelliferone, which has a ﬂuorescence emission at 450 nm (blue color) following excitation at 365 nm. Fluorescent images were taken at 2 min
after adding substrate using epi-ﬂuorescentmicroscopy (40× objective). Themeanﬂuorescence of 50multi-point replicateswas quantiﬁedusing the Image J software.Mean± error bars,
S.E. Thedata are a representation of one out of three independent experiments showing similar results. (B) Insulin-induced sialidase activity in liveHTC-IR cells is blockedby anti-Neu1 and
not with anti-Neu-2, -3, or -4 neutralizing antibodies. Insulin-induced sialidase activity in live HTC-IR cells was measured as described in (A). Cells were either treatedwith 10 nM insulin
plus 50 nM PPP alone, in combination with 100 μg/mL of anti-Neu-1, -2, -3, or -4 neutralizing antibodies or left untreated as control cells. The mean ﬂuorescence of 50 multi-point rep-
licates was quantiﬁed using the Image J software. Mean ± error bars, S.E. The data are a representation of one out of three independent experiments showing similar results. Signiﬁcant
differences at 95% conﬁdence using theDunnett'smultiple comparison testwas used to compare inhibitionwith the insulin control in each group for n=50 replicates. (C) Tamiﬂu inhibits
insulin-induced sialidase activity in HTC-IR cells in a dose dependent manner. Insulin-induced sialidase activity in live cells was measured as described in (A). Fluorescent images were
taken at 2 min after adding 0.318 mM 4-MU substrate together with insulin plus 50 nM PPP and indicated concentrations of Tamiﬂu using epi-ﬂuorescent microscopy (40× objective).
The mean ﬂuorescence surrounding the cells for each of the images was measured using Image J Software. Mean ± error bars, S.E. The data are a representation of one out of three inde-
pendent experiments showing similar results. Signiﬁcant differences at 95% conﬁdence using the Dunnett'smultiple comparison test was used to compare inhibitionwith the insulin con-
trol in each group for n= 50 replicates. (D) Insulin induces sialidase activity in live wild-type human ﬁbroblast cells but not inWG544 or 1140F01 Neu1-deﬁcient ﬁbroblast cells derived
from type 1 sialidosis patients. Insulin-induced sialidase activity in live human ﬁbroblast cells wasmeasured as described in (A). Cells were treatedwith 100 nM insulin or left untreated as
control cells. The data are a representation of one out of four independent experiments showing similar results.
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using 350 μg/mL Tamiﬂu prior to the stimulation with 100 nM of insu-
lin. PPP is a non-competitive inhibitor and was used to discriminate
between insulin receptor and IGF-1R by inhibiting phosphorylation of
IGF-1R tyrosine kinase. Immunocytochemistry analyses demonstrated
that 100 nM of insulin was able to induce the phosphorylation of IRβ
in HTC-IR cells. Tamiﬂu pretreated cells at 350 μg/mL for 35min follow-
ed by 100 nM insulin stimulation for 5 min together with 50 nM PPP
was able to signiﬁcantly inhibit insulin-induced pIRβ activation in
HTC-IR cells (Fig. 2C).3.3. Neu1 is tethered to naive and insulin-stimulated IR receptors
According to the glycosylation model of IR, fourteen of the 18 glyco-
sylation sites are localized on the IRα subunits, while the other sites are
on the IRβ subunits [16]. The IRα subunits contain only the N-linked
carbohydrate, while IRβ subunits contain both O- and N-linked carbo-
hydrates [17]. Studies on mutational analyses of the four glycosylation
sites in IRβ subunit found no effects on the expression of IR on the cell
surface and did not interfere with insulin binding to the IRα subunit,
but the IRβ tyrosine kinase activation by insulin was attenuated [18].
Fig. 2. (A) Tamiﬂu, anti-Neu1 neutralizing antibody and pertussis toxin (PTX) inhibit insulin induced phosphorylation of IGF-1R and IRS-1 in wild-type human ﬁbroblast cells. Cells were
grownovernight on glass coverslips in a 24-well tissue culture plate at 37 °C for 24h or until they reached~70% conﬂuence. Cellswere stimulatedwith 100nM insulin for 5min, pretreated
with either 400 μMTamiﬂu, 100 ng/mL pertussis toxin (PTX), 1.4 μg/mL anti-Neu1 neutralizing antibodies for 30min followedwith 100 nM insulin for 5min or were left untreated as no
ligand controls. Cells were ﬁxed, permeabilized, blocked with 4% bovine serum albumin (BSA) in 0.1% Tween-Tris buffered saline (TBS) for 20min on ice and immunostained with rabbit
anti-phospho-IGF-1R or rabbit anti-phospho-1RS-1 for 60min at 37 °C, followedwith AlexaFluor 594 goat anti-rabbit secondary antibody for 60min at 37 °C. Control group had only sec-
ondary antibodies with no other treatment. Stained cells were visualized by epi-ﬂuorescencemicroscopywith a 40× objective. Quantitative analysis was done by assessing the density of
cell staining corrected for background in each panel using Corel Photo Paint 8.0 software. Each bar in the ﬁgure represents the mean corrected density of culture cell staining ± SEM for
equal cell density (5× 105 cells)within the respective images. The data are a representation of one out of three independent experiments showing similar results. Signiﬁcant differences at
95% conﬁdence using theDunnett'smultiple comparison testwas used to compare inhibitionwith the insulin control in each group for n= 10–20 stained cells. (B) Tamiﬂu inhibits insulin
induced phosphorylation of IRβ (pIRβ) in HTC-IR cells. Cells were cultured on 12mmglass coverslips in a sterile 24 well plate in conditionedmedium. Cells were stimulatedwith 100 nM
insulin plus 50 nM PPP for 5 min, inhibited with 350 μg/mL Tamiﬂu for 35 min followed by stimulation with 100 nM insulin plus 50 nM PPP for 5 min, or left untreated as controls. Cells
were ﬁxed, permeabilized, blocked and immunostained with 4 μg/mL rabbit anti-human phospho-IRβ antibody for 1 h at 37C° followed with AlexaFluor 488 donkey anti-rabbit IgG sec-
ondary antibody for 1 h at 37C°. In order to detect the non-speciﬁc ﬂuorescence background, control cells were incubated with secondary antibody only. Stained cells were visualized by
epi-ﬂuorescencemicroscopy using a 40× objective. Quantitative analysiswas done by assessing the density of cell staining corrected for background in each panel using Corel Photo Paint
8.0 software. Each bar in the ﬁgure represents the mean corrected density of culture cell staining ± SEM for equal cell density (5 × 105 cells) within the respective images. P values rep-
resent signiﬁcant differences at 95% conﬁdence using the Dunnett's multiple comparison test compared to insulin treated cells. (C) Western blot analyses of Tamiﬂu and anti-Neu1 neu-
tralizing antibody inhibition of insulin-induced pIRS-1R in HTC-IR cell lysates. Cell were treatedwith 100 nM insulin plus 50 nMPPP for 5min or pretreatedwith either 400 μMTamiﬂu or
33 μg/mL anti-Neu1 neutralizing antibody for 35min followedwith 100 nM insulin plus 50 nM PPP for 5 min or left untreated as control (media). Cells were pelleted, lysed in lysis buffer
and the cell lysates were resolved by SDS-PAGE. The blot was probed with 4 μg/mL rabbit anti-phospho-1RS-1 antibody for 60 min at 20 °C followed with 40 ng/mL horse radish
peroxidase-labeled goat anti-rabbit antibody for 75 min at 20 °C and Western Lightning Chemiluminescence Reagent Plus for 5 min. The chemiluminescence reaction was analyzed
with X-ray ﬁlm. The blot was re-probed with β-actin as loading control. Quantitative analysis was done by assessing the density of a band corrected for background in each lane using
Corel Photo Paint 8.0 software. Each bar in the graph represents the mean ratio of pIRS1 to β-actin of band density ± S.E. (error bars) for 5–10 replicate measurements. The data are a
representation of one out of three independent experiments showing similar results.
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chains of the IRβ subunits are critical for the IR tyrosine kinase activa-
tion and signal transduction associated with insulin binding to IRα
subunits.
For cell-surface EGF [39] and nerve growth factor (NGF) TrkA [49]
receptors, we reported a receptor signaling paradigm involving a pro-
cess of receptor ligand-induced G-protein coupled receptor (GPCR) sig-
naling via Gαi-proteins, MMP-9 activation, and the induction of Neu1
activation. To test whether this same organizational signaling platformis involved with IR activation, we initially asked whether Neu1
forms a complex with IRβ subunits of insulin receptors. Co-
immunoprecipitation experiments using cell lysates from HTC-IR cells
demonstrated that Neu-1 (Fig. 3A) and not Neu-2 (Fig. 3B) or Neu-4
(Fig. 3C) forms a complex with naive and insulin-stimulated cells. The
data also show that Neu-2 and -4 were present in the whole cell lysates
fromnaive HTC-IR cells. However, wewere unable to detect Neu3 in the
whole cell lysates because the antibodyweakly reacts with Neu-3 (data
not shown). In support of the co-immunoprecipitation results with
Fig. 3. (A) Neu1 co-immunoprecipitateswith IRβ. HTC-IR cells were treatedwith 100 nM insulin for 5, 10 and 15min, or left untreated as control (media). Cells were pelleted, lysed in lysis
buffer and theprotein lysateswere immunoprecipitatedwith 1 μg of rabbit-anti-humanNeu1 antibody,mouse-anti-humanNeu2 antibody, or rabbit anti-humanNeu4 antibody overnight
at 4 °C. Immunocomplexes were isolated using protein G magnetic beads, resolved by SDS-PAGE and the blot probed with either anti-IRβ antibody or indicated anti-Neu1, -2 or -4 anti-
bodies overnight at 4 °C followedbya Clean-Blot IPDetectionReagent for immunoprecipitation/Western blots for 60min andWestern LightningChemiluminescence Reagent Plus. HTC-IR
cells not immunoprecipitated (no IP Ab) served as negative controls.Western blot of cell lysates from naive HTC-IR cellswas run simultaneouswith the immunoprecipitation experiments
in order to determine detectable levels of IRβ proteins. For the IP blots, the blots were washed, stripped and re-probed with anti-Neu-1, -2 or -4 antibodies in order to determine equal
loading. The data are a representation of one out of three independent experiments showing similar results. (B) Neu1 colocalizes with IRβ in naive HTC-IR cells. Cells were ﬁxed, perme-
abilized, and immunostainedwith 4 μg/mL of one of the following combinations of indicated antibodies (anti-IRβwith rabbit-anti-Neu1,mouse-anti-Neu2, goat anti-Neu3, or rabbit anti-
Neu4 antibody) for 60 min at 37 °C. Cells were washed and incubated with 4 μg/mL donkey anti-rabbit AlexaFluor 488, donkey anti-rabbit AlexaFluor 594, donkey anti-goat AlexaFluor
594 antibodies and goat anti-mouse AlexaFluor 594 secondary antibodies for 60min at 37 °C. To account for background non-speciﬁc ﬂuorescence, control cells with only secondary an-
tibody (AlexaFluor 488 or AlexaFluor 594) were used. Stained cells were visualized using a Zeiss Imager M2 ﬂuorescence microscope with 40x objective. Images were processed using
Image J version 1.38x software. To calculate the amount of colocalization in the selected images, the Pearson correlation coefﬁcient was measured and expressed as a percentage using
Image J. The data are a representation of one of three independent experiments showing similar results.
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tion of Neu1 with IRβ. Zeiss M2 Imager ﬂuorescence microscopy re-
vealed the colocalization of Neu1 with IRβ (32% overlay) in naive
HTC-IR cells. There was no colocalization of Neu2 and Neu4 with IRβ
in these cells, which is consistent with the co-immunoprecipitation
ﬁndings. Taken together, these results indicate that Neu1 forms a com-
plex with IRβ subunits of IR on the cell surface prior to ligand binding,
thereby providing conﬁrmation additional to that of previous reports
[34]. These ﬁndings suggest that Neu1 may be a critical requisite inter-
mediate involved in the glycosylation modiﬁcation of insulin receptor
activation.
3.4. Neu1 and matrix metalloproteinase-9 (MMP-9) cross-talk is essential
for insulin-induced IR activation in HTC-IR cells
If Neu1 forms a complex with IRβ subunits of insulin receptors, we
questioned how insulin binding to its receptor activates Neu1. Insight
to this question came from our previous reports demonstrating
a novel Neu1 and MMP-9 cross-talk in alliance with neuromedin
B GPCR identiﬁed by us for EGFR [39] and NGF TrkA [49]. These reports
highlight a receptor signaling paradigm involving a receptor-induced G
protein coupled receptor (GPCR) signaling process and MMP-9 activa-
tion to induce Neu1. This tripartite complex of neuromedin B GPCR,
MMP-9 and Neu1 forms an alliance with the receptor tethered at the
ectodomain on the cell surface. Active Neu1 in complex with the recep-
tor hydrolyzes α-2,3-sialyl residues, enabling removal of steric hin-
drance of receptor association and allowing subsequent dimerization,
activation, and cellular signaling.We have previously reported the strik-
ing similarity between this novel receptor signaling platform for cell
surface Toll-like receptor (TLR)-4 [48,50,51,54,68] and intracellular
TLR-7 and TLR-9 receptors [52]. Based on these ﬁndings, we asked
whether Neu1 is also connected with MMP-9 and GPCR for ligand-induced IRβ subunits. Indeed, insulin was reported to induce MMP-9
via mitogenic signaling pathways in monocytes, whereas the phos-
phatidylinositol 3-kinase-dependent signaling cascadewhich is typical-
ly altered in insulin resistance was not involved [69]. It was proposed
that the induction of MMP-9 by insulin may potentially contribute to a
pro-inﬂammatory state with increased cardiovascular morbidity and
mortality in type 2 diabetics [69]. Furthermore, the enhanced proteolyt-
ic activity in the microcirculation of spontaneously hypertensive rats
(SHRs) was reported to contribute to the pathophysiological mecha-
nism causing cell membrane receptor cleavage [70]. The hypertensive
rats had elevated leukocyte countswhichwere accompanied bydegran-
ulation and release of proteases from lysosomal granules of neutrophils
[71]. These latter results suggest that elevated MMP activity such as
gelatinase B (MMP-9) [72,73] in themicrocirculation of these hyperten-
sive rats leads to proteolytic cleavage of cell surface membrane recep-
tors including the cleavage of the IRα subunit binding domain [70].
Accordingly, we propose a Neu1-MMP-9 cross-talk in alliance with
GPCR that is required for insulin activation of IRβ.
To test this hypothesis, the inhibitory effect of the broad range MMP
inhibitors, galardin (GM6001) and piperazine aswell as theMMP3 spe-
ciﬁc inhibitor (MMP3i) on sialidase activity associated with insulin-
stimulated live HTC-IR cells was examined. The data shown in Figs. 4
and 5 show that piperazine (PIPZ, Fig. 4A), galardin (Fig 4B) and
MMP9 inhibitor (MMP9i, Fig. 5A) except for MMP3i (Fig. 4C) dose-
dependently inhibited the sialidase activity associated insulin-treated
live HTC-IR cells compared to the no ligand control levels. Galardin
and piperazine had an IC50 of 32 μM and 15 μM, respectively, which is
comparable to an IC50 of 4.89 μM for MMP9i. For MMP3i, the IC50 was
N146 μM.
Western blot analyses using cell lysates from HTC-IR cells clearly
showed that MMP9i at 50 and 100 μg/mL inhibited insulin-induced
pIRS1 in these cell lysates (Fig. 5B). Together, the additional intracellular
Fig. 4. Insulin-induced sialidase activity in live HTC-IR cells is inhibited by (A) piperazine (PIPZ), (B) galardin (GM6001) but not by (C) speciﬁcMMP-3 inhibitor in a dose-dependentman-
ner. After removingmedium, 0.2mM4-MUNANA substrate in Tris-buffered saline, pH7.4,was added to cells alone (control), with 10nM insulin plus 50 nMPPP, orwith insulin plus PPP in
combination with piperazine (PIPZ), galardin or MMP-3i at the indicated concentrations. Fluorescent images were taken at 1 min after adding substrate using epi-ﬂuorescentmicroscopy
(40× objective). Themean ﬂuorescence surrounding the cells for each of the imageswasmeasured using Image J software.Mean± error bars, S.E. The data are a representation of one out
of three independent experiments showing similar results. Signiﬁcant differences at 95% conﬁdence using the Dunnett'smultiple comparison test was used to compare inhibitionwith the
insulin control in each group for n = 50 replicates.
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ed cross-talk between Neu1 and MMP-9 crosstalk tethered to IRβ sub-
units (Fig. 5C). Co-immunoprecipitation experiments using cell lysates
from HTC-IR cells demonstrated that MMP-9 forms a complex with
naive and insulin-stimulated IRβ (Fig. 5D).
The inhibitory effect of neuromedin B GPCR speciﬁc antagonist BIM-
23127 on sialidase activity associated with bombesin-stimulated live
HTC-WT cells was examined. The data shown in Fig. 6 show that BIM-
23127 at 333 μg/mL signiﬁcantly inhibited the sialidase activity associ-
ated bombesin-treated live HTC-WT cells comparable to the no ligand
control levels. Co-immunoprecipitation experiment using cell lysates
from HTC-WT cells demonstrated that neuromedin B GPCR forms a
complex with naive and insulin-stimulated IRβs (Fig. 6B). Collectively,
the additional intracellular and cell-surface colocalization of Neu1 and
MMP-9 validated the predicted cross-talk between the neuromedin
B GPCR–MMP-9–Neu1 tripartite complex tethered to IRβ subunits of in-
sulin receptors.
3.5. Olanzapine-induced Neu3 sialidase activity attenuates insulin-induced
IRβ and IRS1 phosphorylation contributing to insulin resistance
Disturbances in glucose homeostasis and metabolism in patients
with schizophrenia during antipsychotic treatment with olanzapine
are mainly due to insulin resistance [40–42] whereas the function ofthe beta cell was unaffected in olanzapine-treated patients. Themecha-
nism(s) behind olanzapine-induced insulin resistance in these patients
is unknown. It has been reported that insulin-induced IRS-1 tyrosine
phosphorylation in L6 myotubes was increased several fold, and
olanzapine inhibited insulin-stimulated IRS-1-associated PI3K activity
in a dose-dependent manner [42]. Here, we investigated the molecular
mechanism(s) behind olanzapine-induced insulin resistance. As shown
in Fig. 7A and B, olanzapine stimulation of live 1140F01 Neu1-deﬁcient
cells as well as primary bone marrow (BM) murine macrophage cells
derived from Neu4 knockout (KO) mice induced sialidase activity
which was inhibited by the Neu3 inhibitor, DANA (2-deoxy-2,3-
dehydro-N-acetylneuraminic acid) [74] and anti-Neu3 neutralizing
antibodies. In addition, immunocytochemistry analyses of wild-type
ﬁbroblast pretreated with olanzapine or anti-Neu1 antibodies attenuat-
ed phosphorylation of IGF-R and IRS1 associated with insulin-
stimulated human ﬁbroblast cells. Based on these results, we propose
that olanzapine-induced Neu3 sialidase activity down-regulates Neu1,
the inhibition of which attenuated insulin-induced IGF-R and IRS1
phosphorylation contributing to insulin resistance.
4. Discussion
The molecular mechanism(s) by which IRs become activated is not
well understood. There is substantial evidence to indicate that insulin
Fig. 5. (A) SpeciﬁcMMP-9 inhibitor blocks dose-dependently insulin-induced sialidase activity in live HTC-IR cells. After removingmedium, 0.2mM4-MUNANA substrate in Tris-buffered
saline, pH 7.4, was added to cells alone (control), with 10 nM insulin plus 50 nM PPP, or with insulin plus PPP in combination with MMP-9i at the indicated concentrations. Fluorescent
images were taken at 1 min after adding substrate using epi-ﬂuorescent microscopy (40× objective). The mean ﬂuorescence surrounding the cells for each of the images was measured
using Image J software.Mean± error bars, S.E. The data are a representation of one out of three independent experiments showing similar results. Signiﬁcant differences at 95% conﬁdence
using the Dunnett's multiple comparison test was used to compare inhibition with the insulin control in each group for n= 50 replicates. (B)Western blot analyses ofMMP9i on insulin-
induced IRS-1R phosphorylation (pIRS-1R) in HTC-IR cells. Cells were left untreated (control), stimulated with 100 nM insulin plus 50 nM PPP for 5 min, or pretreated with 50 μg/mL or
100 μg/mLMMP9i for 35min followedwith 100 nM insulin plus 50 nMPPP for 5min. Cells were pelleted, lysed in lysis buffer and the cell lysateswere resolved by SDS-PAGE. The blotwas
probed with rabbit anti-human pIR-S1 antibody overnight at 4 °C. The blot was incubated with secondary HRP conjugated goat anti-rabbit IgG antibody for 60min at room temperature
and Western Lightning Chemiluminescence Reagent Plus. The chemiluminescence reaction was analyzed with X-ray ﬁlm. The blot was re-probed with β-actin as loading control. Quan-
titative analysiswas done by assessing the density of a band corrected for background in each lane using Corel Photo Paint 8.0 software. Each bar in the graph represents themean ratio of
pIRS1 toβ-actin of banddensity± S.E. (error bars) for 5–10 replicatemeasurements. Thedata are a representation of one out of three independent experiments showing similar results. (C)
MMP9 colocalizes with IRβ in naive HTC-IR cells. Cells were cultured on 12 mm glass coverslips in a sterile 24 well plate in conditioned medium as described. Cells were ﬁxed, perme-
abilized and blocked with 4% bovine serum albumin (BSA) in 0.1% tween-TBS. Cells were incubated with 4 μg/mL of rabbit anti-IRβ antibody and goat anti-MMP9 antibody for 60 min
at 37 °C. Cells were washed and incubated with 4 μg/mL of AlexaFluor 594 conjugated donkey anti-goat IgG and AlexaFluor 488 conjugated donkey anti-rabbit IgG for 60 min at 37 °C.
To account for background non-speciﬁc ﬂuorescence, control cells with only secondary antibody (AlexaFluor 488 or AlexaFluor 594) were used. Stained cells were visualized using a
Zeiss Imager M2 ﬂuorescence microscope with 40× objective. Images were processed using Image J version 1.38x software. To calculate the amount of colocalization in the selected im-
ages, the Pearson correlation coefﬁcient wasmeasured and expressed as a percentage using Image J. The data are a representation of one of three independent experiments showing sim-
ilar results. (D) IRβ co-immunoprecipitateswithMMP9 innaive and insulin-stimulatedHTC-IR cells. Cellswere left unstimulated as a control or stimulatedwith 100 nM insulin plus 50nM
PPP for 5,10 or 15 min. Cells were pelleted, lysed in lysis buffer and the protein lysates were immunoprecipitated with 1 μg of goat anti-MMP9 antibody overnight at 4 °C.
Immunocomplexes were isolated using protein G magnetic beads, resolved by SDS-PAGE and the blot probedwith anti-IRβ antibody overnight at 4 °C followed by a Clean-Blot IP Detec-
tion Reagent for immunoprecipitation/western blots for 60min andWestern Lightning Chemiluminescence Reagent Plus. HTC-IR cells not immunoprecipitated (no IP Ab) served as neg-
ative controls. For the IP blots, the blots were washed, stripped and re-probed with anti-MMP9 antibodies in order to determine loading. The data are a representation of one out of three
independent experiments showing similar results. The chemiluminescence reaction was analyzed with X-ray ﬁlm. The data are a representation of one out of three independent exper-
iments showing similar results.
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between ligand-binding and activation [16,18–20,24,34]. However, the
parameters controlling interactions between the receptors and insulin
to facilitate receptor activation remained poorly deﬁned until now.
The ﬁndings in this report uncover amolecular organizational GPCR sig-
naling platform of a novel Neu1 and MMP-9 cross-talk in alliance with
IRβ subunits on the cell surface of IR-expressing cells that is essential
for insulin activation of IRs and subsequent cellular signaling. At the ge-
netic level, the sialidase activity associated with insulin stimulation of
human WG544 and 1140F01 type 1 sialidosis ﬁbroblast cell lines wascompletely abrogated. These sialidosis ﬁbroblast cells were obtained
from patients with type 1 sialidosis or mucolipidosis-1 who have a
true Neu1 deﬁciency [44]. The data further indicate that Neu1 forms a
complex with the IRβ subunits of the receptor on the cell surface prior
to ligand binding, thereby providing conﬁrmation additional to that of
previous reports [12,34]. The report by Dridi et al. provided evidence
to demonstrate that Neu1 deﬁcient mice with ∼ 10% of the normal
Neu1 activity exposed to a high-fat diet developed hyperglycemia and
insulin resistance twice as fast as the wild-type cohort [34]. In addition,
mutational analyses targeting IRβ subunitswhichweremutagenized on
Fig. 6. (A) Insulin- andbombesin-induced sialidase activity in liveHTC-WTcells are inhibitedbyTamiﬂuand selectiveneuromedinBGPCR antagonist BIM-23127. After removingmedium, 0.2mM
4-MUNANA substrate in Tris-buffered saline, pH 7.4, was added to cells alone (control), with 100 nM insulin plus 50 nM PPP, or with insulin plus PPP in combination with 200 μg/mL
Tamiﬂu or 333 μg/mL BIM-23127. Fluorescent images were taken at 1 min after adding substrate using epi-ﬂuorescent microscopy (40× objective). The mean ﬂuorescence surrounding
the cells for each of the imageswasmeasured using Image J software. Mean± error bars, S.E. The data are a representation of one out of three independent experiments showing similar
results. (B) Neuromedin B GPCR (NMBR) co-immunoprecipitateswith IRβ and verse versa in naive and insulin-stimulatedHTC-WT cells. Cellswere left unstimulated as amedia control or
stimulated with 100 nM insulin plus 50 nM PPP for 5 min. Cells were pelleted, lysed in lysis buffer and the protein lysates were immunoprecipitated with 1 μg of anti-IRβ antibody over-
night at 4 °C. Immunocomplexes were isolated using protein G magnetic beads, resolved by SDS-PAGE and the blot probed with anti-NMBR antibody overnight at 4 °C followed by a
Clean-Blot IP Detection Reagent for immunoprecipitation/western blots for 60 min andWestern Lightning Chemiluminescence Reagent Plus. The chemiluminescence reaction was ana-
lyzed with X-ray ﬁlm. Cells not immunoprecipitated (no Ab) served as negative controls. The data are a representation of one out of three independent experiments showing similar
results.
Fig. 7. Olanzapine induces sialidase activity in live (A) 1140F01 Neu1-deﬁcient human ﬁbroblast cells derived from type 1 sialidosis patients and (B) primary bone marrow macrophage
cells derived from Neu4 knockout mice. Cells were treated with 100 nM insulin, 10 μg/mL olanzapine, pretreated with olanzapine with 200 μg/mL DANA or 62.5 μg/mL anti-Neu3 anti-
bodies or left untreated as control cells. The data are a representation of one out of four independent experiments showing similar results. (C) Olanzapine and anti-Neu1 neutralizing an-
tibody inhibit insulin induced phosphorylation of IGF-1R and IRS-1 in wild-type human ﬁbroblast cells. Cells were grown overnight on glass coverslips in a 24-well tissue culture plate at
37 °C for 24 h or until they reached ~70% conﬂuence. Cells were stimulated with 100 nM insulin for 5 min, pretreated with either 100 μMolanzapine or 1.4 μg/mL anti-Neu1 neutralizing
antibodies for 30min followedwith 100 nM insulin for 5min orwere left untreated as no ligand controls. Cells were ﬁxed, permeabilized, blockedwith 4% bovine serum albumin (BSA) in
0.1% Tween-Tris buffered saline (TBS) for 20min on ice and immunostained with rabbit anti-phospho-IGF-1R or rabbit anti-phospho-1RS-1 for 60 min at 37 °C, followedwith AlexaFluor
594 goat anti-rabbit secondary antibody for 60min at 37 °C. Control group had only secondary antibodies with no other treatment. Stained cells were visualized by epi-ﬂuorescence mi-
croscopy with a 40× objective. The data are a representation of one out of three independent experiments showing similar results.
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activation by insulin [18]. Collectively, our data provide additional evi-
dence to demonstrate that a tripartite complex of neuromedin
B GPCR–MMP-9–Neu1 is tethered to IRβ subunits of insulin receptors.
This signaling paradigm proposes that insulin binding to its receptor
on the cell surface induces a conformational change of the receptor to
initiate GPCR-signaling and MMP-9 activation to induce Neu1. There is
substantial evidence strongly to demonstrate that insulin binding to
the receptor induces a conformational change (a) at the C terminus do-
main [75], (b) increases the rate of autophosphorylation rather than in-
creases ATP afﬁnity [76], (c) involves a fast bimolecular binding reaction
followed by a slower unimolecular step representing a conformational
change in the insulin-receptor complex [77], and (d) favors a basal-
state conformation of the activation loop that is more accessible over-
coming the intra-sterically inhibitory conformation that encompasses
≥90% of the ligand-free basal state kinase [78]. Based on mutagenesis
studies on the four N-glycosylation sites (IRβ-N1234) of the IRβ subunit
of the receptor [18], the intra-sterically inhibitory ligand-free basal state
kinase is most likely under the control of α-2,3 sialic acid residues of
IRβ, and the kinase activation state induced by insulin is regulated by
Neu1 sialidase activity in hydrolyzing these sialic residues and remov-
ing steric hindrance of the activation loop as shown by our data.
Structurally, the insulin receptor is composed of a heterotetramer
consisting of two αβ dimers [79]. Disulﬁde bridges connect the αβ
subunits within the dimer as well as the IRα subunits of αβ dimers
within the tetramer [80]. The IRα subunit is extracellular and provides
the insulin binding site. The IRβ subunit contains a short extracellular
region, a transmembrane segment and an intracellular tyrosine kinase
domain. Analysis of these structures suggests that an insulin-induced
conformational change in the dimeric structure may change the
relative orientation of the tyrosine kinases leading to trans-
autophosphorylation and activation of the receptor [81,82]. The molec-
ular mechanism(s) involved in the orientation of the activation loop
containing the tyrosine kinases was unknown until now.
This report proposes a novel molecular organizational GPCR signal-
ing platform for the IRβ subunits. It is based on the ﬁndings that Neu1
and MMP-9 are already in complex with the ligand-free basal state
IRβ, and are rapidly induced upon insulin binding to the extracellular
IRα subunit. Activated Neu1 speciﬁcally hydrolyzes α-2,3-sialyl resi-
dues linked to β-galactoside of the ligand-free basal state kinases of
the activation loop, which are distant from ligand binding. This process
enables removal of steric hindrance for proper orientation of the tyro-
sine kinases leading to trans-autophosphorylation and activation of
the receptor and subsequent IR signaling cascades. The ﬁndings in this
report also provide evidence for MMP-9 involvement in the insulin
activation of IRβ. We have reported that Neu1 in alliance with GPCR-
signaling Gαi subunit proteins and MMP-9 is expressed on the cell sur-
face of EGFR- [39], TrkA- [49], and TLR- [51,52] expressing cells. This
tripartite alliance makes Neu1 readily available to be induced by ligand
binding to the receptor. Our data support this premise. How Neu1
sialidase is rapidly induced byMMP-9 together with GPCR Gαi- subunit
proteins still remains unknown. It can be speculated that insulin binding
to IRα subunits on the cell surface initiates GPCR-signaling to activate
MMP-9. Our data using co-immunoprecipitation of IRβ and neuromedin
B GPCR suggest that the neuromedin B GPCR forms a complex with
naive and insulin-induced IR activation in HTC-WT cells (see Fig. 6B).
Indeed, it has been reported that neuromedin B receptor knockout
(NBR-KO) female mice did not change body weight and homeostasis
fed a normolipid diet, but they did developed partial resistance to
diet-induced obesity [83]. The GPCR signal integration in insulin recep-
tor activation is eloquently reviewed by Patel [84] and Abdulkhalek
et al. [33]. Since both MMP-9 and NMBR form a complex with IRβ sub-
units, they are also associatedwith each other. Co-immunoprecipitation
experiments using cell lysates from RAW-Blue cells demonstrated that
the neuromedin BGPCR80 kDa isoform forms a complexwith the active
88 kDa MMP9 isoform from naive or lipopolysaccharide (LPS)-stimulated cells [68]. These data further validated that neuromedin B
GPCR forms a complex with MMP-9 on the cell surface of naive cells.
The data in the report also showed that GPCR agonists such as
bombesin, lysophosphatidic acid (LPA), cholesterol, angiotensin-1 and
-2, and bradykinin binding to their respective GPCR receptors induced
Neu1 activity within 1 min and that this activity was blocked by Gαi-
sensitive pertussis toxin, neuraminidase inhibitor Tamiﬂu, broad-
range MMP inhibitors galardin and piperazine, anti-Neu1 and anti-
MMP-9 antibodies, and siRNA knockdown of MMP-9. The rapidity of
the GPCR agonist-induced Neu1 activity suggests that glycosylated re-
ceptors like TLRs as well as receptor tyrosine kinases form a functional
GPCR-signaling complex. Indeed, Gilmour et al. [39] and Moody et al.
[85] have reported that the neuromedin B GPCR regulates EGF receptors
by a mechanism dependent on MMP activation. It is well known that
agonist-bound GPCRs have been shown to activate numerous MMPs
[86], including MMP-3 [87], MMPs 2 and 9 [88,89], including the mem-
bers of the ADAM family of metalloproteinases [90,91]. We have shown
that GPCR agonists can directly activate Neu1 through the intermediate
MMP-9 in order to induce transactivation of TLRs and subsequent cellu-
lar signaling [52,68]. It is noteworthy that insulin can mediate increases
in MMP-9 via IR activation [69], which ﬁts well within our molecular
signaling platform of Neu1-MMP-9 cross-talk in regulating insulin-
induced receptors. That study has also shown that insulin can induce
MMP-9 via the mitogenic signaling pathways, whereas the phos-
phatidylinositol 3-kinase-dependent signalingwhich is typically altered
in insulin resistance is not required [69]. The connection between GPCR
and IR has also been demonstrated for β-adrenergic receptors tethering
to IR in adipocytes [92–95]. These reports showed that insulin binding
IR stimulates the phosphorylation of the β-adrenergic receptor on Tyr-
350 and this process facilitates IR tethering to β-adrenergic receptor
via growth factor receptor-bound protein 2 (Grb-2). This molecular
signaling platform integrating the IR/β-adrenergic receptor/Grb-2 tri-
partite complex is critical for β-adrenergic agonist ampliﬁcation of
insulin-dependent activation of p42/p44 MAPK. The premise behind
this molecular signaling platform is to improve IR signaling in our pres-
ent study and others [92–95], but also in other RTKs like PDGFβR [25]
with a GPCR. This latter study demonstrated that PDGF induced a stron-
ger tyrosine phosphorylation of Gαi and a more robust activation of
p42/p44 MAPK in cells transfected with both PDGFβR and EDG-1, the
GPCR for SIP-1, compared with PDGFβR alone. These RTK–GPCR signal-
ing platforms are eloquently reviewed by Pyne and Pyne [30].
If Neu1 sialidase is playing a major role in the activation of IR as our
data suggest and by others [34], logistically Neu1 may be the potential
target for insulin resistance. Here, we used a known antipsychotic
drug that induces insulin resistance in patients with schizophrenia
[40–42], which was not due a malfunction of the β cell. The mecha-
nism(s) behind olanzapine-induced insulin resistance in these patients
is unknown. At the genetic level, we have shown that olanzapine
induces Neu3 sialidase activity inNeu1-deﬁcient human sialidosisﬁbro-
blast cells and in Neu4 knockout primary macrophage cells. Wild-type
human ﬁbroblast cells pretreated with olanzapine attenuated phos-
phorylation of IGF-R and IRS1 associated with insulin-stimulated cells.
Collectively, olanzapine-induced Neu3 sialidase activity is proposed to
down-regulate Neu1, the inhibition of which attenuates insulin-
induced IGF-R and IRS1 phosphorylation and contributing to insulin
resistance. Indeed, Neu3 has been shown to participate in the control
of insulin signaling, most likely via the modulation of gangliosides and
the interaction with growth factor receptor-bound protein 2 (Grb2)
[24]. That report also showed that the transient transfection of Neu3
into 3T3-L1 adipocytes and L6 myocytes caused a signiﬁcant decrease
in IR signaling. Another report has shown that overexpression of Neu3
sialidase inhibits MMP-9 expression in vascular smooth muscle cells
[96]. Recently, itwas shown that chow-fedmice given acute and chronic
intravenous injections of elastin-binding peptides developed hypergly-
cemia and insulin resistance [12]. The report proposed that this insulin
resistance is due to the interaction of IR with Neu1 subunit of the elastin
1367F. Alghamdi et al. / Cellular Signalling 26 (2014) 1355–1368receptor complex triggered by elastin-binding peptides. In another
report by these authors, it was shown that following elastin peptide
treatment, the cellular GM3 levels decreased while lactosylceramide
(LacCer) content increased consistently with a GM3/LacCer conversion
[97]. It was suggest that Neu-1-dependent GM3/LacCer conversion is
the key event leading to signaling by the elastin receptor complex.
Based on these latter results, an alternate interpretation of the role of
elastin-binding peptides in insulin resistance may involve the mecha-
nismof directmodulation of plasmamembrane gangliosides by increas-
ing Neu3 activity and the interaction of which is facilitated by the
growth factor receptor-bound protein 2 (Grb2) as described elsewhere
[24].
In the present study, olanzapine-induced Neu3 sialidase activity
down-regulates Neu1 by inhibiting MMP9 activation and thereby,
disrupting the Neu1–MMP9-neuromedin B GPCR signaling platform
tethered to IRβ subunits in the activation of insulin receptors. We pro-
pose here that a negative unbalance of this novel IRβ subunit signaling
platform critical for the insulin receptor contributes to insulin resistance
and type 2 diabetes.
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